Caduet Combination Tablets are oral combination drug of Norbasc Tablets and Lipitor Tablets.
Under the agreement, Pfizer is responsible to seek marketing approval for the product in Japan, effective 1 October 2011.
According to the new agreement, Astellas will acquire all the distribution rights of Caduet Combination Tablets from 1 October 2011 and will book its sales which are currently booked by Pfizer.
Additionally, Astellas will advance its promotional activity to enhance the product value of Caduet Combination Tablets.